Am Heart J. 2015;169:647 54. Yancy et al Appendix 1. Author Relationships With Industry and Other Entities (Relevant) 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure (December 2015) Committee Member Employment Consultant Speakers Bureau Ownership/ Partnership/ Principal Personal Research Institutional, Organizational, or Other Financial Benefit Expert Witness Voting Recusals By Section* Clyde W. Yancy, Chair Northwestern University Feinberg School of Medicine, Division of Cardiology Professor of Medicine and Chief; Diversity and Inclusion Vice Dean None None None None None None None Mariell Jessup, Vice Chair Fondation Leducq Chief Scientific Officer None None None None None None None Biykem Bozkurt Baylor College of Medicine, Department of Medicine Professor of Medicine; Cardiology Section, DeBakey VA Medical Center Chief; The Mary and Gordon Cain Chair & W.A. Tex and Deborah Moncrief, Jr. Chair; Winters Center for Heart Failure Research Director; Cardiovascular Research Institute Associate Director None None None Novartis None None 7.3.2.10, 9.5. Javed Butler Stony Brook University Division Chief of Cardiology Bayer Boehringer Ingelheim CardioCell Luitpold Medtronic Merck Novartis Relypsa Takeda Trevena Z Pharma Zensun Novartis None Amgen (DSMB) None None 7.3.2.10, 9.5. Donald E. Casey, Jr Thomas Jefferson College of Population Health Faculty; Alvarez & Marsal Founder None None None None None None None Monica M. Colvin University of Michigan Associate Professor of Medicine, Cardiology None None None None None None None Mark H. Drazner University of Texas Southwestern Medical Center Professor, Internal Medicine None None None None None None None Gerasimos S. Filippatos National and Kapodistrian University of Athens; Attikon University Hospital, Department of Cardiology, Heart Failure Unit Professor of Cardiology None None None Bayer Bayer (DSMB) Novartis Servier Pharmaceuticals Vifor None None 7.3.2.10, and 9.5. 